886372-05-0

Basic information

• Product Name: 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER
• Synonyms: 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER;4-Chloro-6-methyl-3-pyridinecarboxylic acid methyl ester
• CAS NO: 886372-05-0
• Molecular Formula: C₈H₈ClNO₂
• Molecular Weight: 185.60762
• Mol File: 886372-05-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 242.7 °C at 760 mmHg
• Flash Point: 100.6 °C
• Appearance: /
• Density: 1.247 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER(886372-05-0)
• EPA Substance Registry System: 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER(886372-05-0)

Safety Data

• Hazardous Substances Data: 886372-05-0(Hazardous Substances Data)

Usage

General Description

4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER is a chemical compound with the molecular formula C10H9ClNO2. It is a methyl ester derivative of 4-chloro-6-methyl-nicotinic acid, which is a derivative of nicotinic acid. 4-CHLORO-6-METHYL-NICOTINIC ACID METHYL ESTER is commonly used in the synthesis of pharmaceuticals and agrochemicals due to its potential biological activity. It may have applications in the development of new drugs and pesticides, as well as in research and development studies. Additionally, it is important to handle this chemical compound with care, as it may pose health risks and environmental hazards if not properly managed.

Upstream product

• 67-56-1 methanol 
• 1060805-95-9 4-chloro-6-methylnicotinic acid 
• 1005515-30-9 4‐chloro‐6‐methylpyridine‐3‐carbonyl chloride 
• 67367-33-3 4-hydroxy-6-methylnicotinic acid 
• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 33821-58-8 6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 
• 823-96-1 Trimethylboroxine 

Downstream Products

• 1454914-31-8 (4-(4-chloro-2-fluorophenyl)-6-methylpyridin-3-yl) methanol 
• 1454914-30-7 methyl 4-(4-chloro-2-fluorophenyl)-6-methylnicotinate 
• 1616293-35-6 6-phenoxymethyl-3,4-dihydro-2H-[2,7]naphthyridin-1-one 
• 1616293-36-7 2-methyl-6-phenoxymethyl-3,4-dihydro-2H-[2,7]naphthyridin-1-one 
• 1616293-37-8 6-phenoxymethyl-2(R)-(1,2,2-trimethyl-propyl)-3,4-dihydro-2H-[2,7]naphthyridin-1-one 
• 1616293-38-9 2-(4-fluorophenyl)-6-phenoxymethyl-3,4-dihydro-2H-[2,7]-naphthyridin-1-one 
• 1629239-91-3 4-chloro-6-phenoxymethyl-nicotinic acid methyl ester 
• 1629240-46-5 6-phenoxymethyl-4-vinyl-nicotinic acid methyl ester 
• 1357946-60-1 6-methyl-1H-pyrazolo[4,3-c]pyridine 
• 143806-23-9 4-phenyl-6-methylnicotinic acid methyl ester 

Relevant articles and documents

NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.